(Q38693911)

5 September 2017

Postmarket policy considerations for biosimilar oncology drugs (English)

1 reference

5 September 2017

Matthew J Renwick

1

1 reference

5 September 2017

Kate Smolina

2

1 reference

5 September 2017

Emilie J Gladstone

3

1 reference

5 September 2017

Deirdre Weymann

4

1 reference

5 September 2017

Steven G Morgan

5

1 reference

5 September 2017

23 December 2015

1 reference

Lancet Oncology Commission

5 September 2017

1 reference

5 September 2017

17

1 reference

5 September 2017

1

1 reference

5 September 2017

e31-8

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

5 September 2017

1 reference

7 January 2021

Biosimilars: how similar?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Controlling the cost of innovative cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

The economic pressures for biosimilar drug use in cancer medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Basic facts about biosimilars

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Regulatory and clinical considerations for biosimilar oncology drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Interchangeability, immunogenicity and biosimilars

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

The safety of switching between therapeutic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Statistical and regulatory considerations in assessments of interchangeability of biological drug products

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Pure red-cell aplasia and epoetin therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: an open-label, randomized-sequence, three-treatment, three-way cros

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Risk management of biosimilars in oncology: each medicine is a work in progress

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Risk Management Plans: are they a tool for improving drug safety?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Barriers to the uptake of biosimilars and possible solutions: a Belgian case study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

The market for follow-on biologics: how will it evolve?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Reimbursement of pharmaceuticals: reference pricing versus health technology assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Developing oncology biosimilars: an essential approach for the future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

Developing the nation's biosimilars program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900381-2

7 January 2021

10.1016/S1470-2045(15)00381-2

Identifiers

DOI

1 reference

release_fea2er3x7vawtoyqsmknsibuoq

5 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fea2er3x7vawtoyqsmknsibuoq

24 November 2022

mapped directly with Wikidata item

1 reference